anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject composition of high stability, useful as a medicine by incorporating a polypeptide with human serum albumin, and further adding sugar or sugar alcohol, followed by lyophilization and then converting the product to a fine powdered form. CONSTITUTION:A polypeptide (e.g. human interferon alpha) is incorporated with (A) >=0.5wt.%, based on said polypeptide, of human serum albumin and (B) 0.01-200wt.%, based on said polypeptide plus human serum albumin, of sugar or a sugar alcohol (e.g. sorbitol) followed by lyophilization. The product is then converted to fine powder using e.g. a jet milling equipment. The particle size is so regulated that the particles 0.5-4.0mum in size account for >=50wt.% of the total particles for transpulmonary administration, whereas the particles 4.0-10mum in size >=50wt.% for the administration via phrynx route. The lyophilized product thus converted to fine powder is formulated with a surfactant for improving the dispersivility of powder and also, where apropriate, with mineral ion(s), etc., thus obtaining the objective composition.
Cognitive behavioral therapy (CBT) is the current evidence-based treatment for HD but the majority of sufferers remain symptomatic after CBT with impairing levels of clutter in their homes. Home visits, with a focus on in-home decluttering, have in previous research been shown to be a promising intervention when combined with CBT. However, augmenting CBT with subsequent home visits has not yet been tested in a randomized controlled trial (RCT). In response to this, in this trial, we aim to investigate the efficacy of a coordinated intervention, consisting of CBT and in-home decluttering for HD, in an RCT. In this trial, 90 participants with HD will initially receive 12 sessions of CBT through a psychiatric outpatient service. After CBT, participants will be randomized to receive either 10 home visits in 10 weeks, or to a wait list condition. Our hypothesis is that augmenting CBT with home visits will lead to a reduction in hoarding symptoms and clutter and improved daily functioning compared to wait list. We will also investigate the cost-economical aspects of the intervention. Results from this trial have the potential to reveal whether in-home decluttering should be added to CBT in order to reduce symptoms of hoarding and improve function in indviduals with HD.
BACKGROUND Clostridium ramosum is an anaerobic, spore-producing, gram-positive rod, enteric pathogen that is difficult to identify and is rarely pathogenic. We present a case of Clostridium ramosum bacteremia secondary to aspiration pneumonia in a 65-year-old immunocompromised man on chemotherapy for follicular lymphoma. CASE REPORT We report the case of a 65-year-old man, on active chemotherapy for follicular lymphoma, presenting with a fever of 38.3°C, nonproductive cough, fatigue, and confusion. Physical examination was unremarkable except for +2 lower-extremity pitting edema. CT abdomen pelvis showed left lower-lung consolidation and CT chest angiogram showed that the consolidation was concerning for infarct verses abscess and segmental/subsegmental pulmonary emboli despite anticoagulation use. Blood cultures later grew Clostridium ramosum, which was successfully treated with IV piperacillin-tazobactam. Subsequent outpatient imaging demonstrated resolution of the lung consolidation. CONCLUSIONS Our case highlights the rare diagnosis of Clostridium ramosum bacteremia secondary to aspiration pneumonia in an immunocompromised patient and our approach to management. We highlight the difficulties in identification of Clostridium ramosum, rare pathogenicity, risk factors, and potential sources.
Increases in serum transaminases have been reported with use of ZOCOR [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. Persistent increases to more than 3xULN in serum transaminases have occurred in approximately 1% of patients receiving ZOCOR in clinical studies. Marked persistent increases of hepatic transaminases have also occurred with ZOCOR. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including ZOCOR.

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.

Consider liver enzyme testing before ZOCOR initiation and when clinically indicated thereafter. ZOCOR is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZOCOR.
PROBLEM TO BE SOLVED: To obtain the subject composition useful as a preparation for glutamine-containing nutritive solutions, suitable for use after dissolved in a physiological solution such as water or electrolytic solutions when to be used, by including a specific solid glutamine. SOLUTION: This composition is obtained by including a solid glutamine prepared in the form of a solid from (A) glutamine in the presence of (B) a pref. water-soluble substance permissible as a medicine other than the ingredient A. The solid glutamine is pref. a lyophilized glutamine obtained by lyophilizing the ingredient A in the presence of the ingredient B in a molar ratio the ingredient B/the ingredient A of >=0.2, pref. >=0.8, more pref. >=1.0, most pref. >=1.2. As the ingredient B, a composition usable in injections, especially, e.g. an isotonizing agent is pref. used. Examples of the ingredient B include, for example, a saccharide, an inorganic salt and amino acid.
On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
Osteoporosis is a skeletal disease characterized by a low bone mass, deterioration of the bone structure and an increased risk of bone fracture. Although jaws are not at risk of fracture, they revealed changes due to the disease. Bisphosphonates are the most common medical therapy for osteoporosis as they improve bone structure and reduce its absorption. From a periodontal point of view, it was suggested as an adjunctive therapy for periodontal bone loss. Controversy exists regarding their effects, however. In addition, their effects on the periodontal status and jaw bones are unknown when these drugs are prescribed for treating osteoporosis, i.e. not for periodontal purposes. It is also unknown whether their effects on alveolar bone, if any, can be detected by simple radiographs (such as panoramic radiographs) or required advanced techniques (e.g. Cone-beam CT).

In this study, their effects on alveolar bone are going to be evaluated using panoramic radiography and Cone-beam CT, as well as the clinical parameters of periodontal diseases. Cone-beam CT will also offer a way to compare bone histomorphometry of the jaws between groups. Bisphosphonates will be prescribed by physicians of osteoporotic women. The investigators will not interfere drug administration at all. Thus, the investigators can test their indirect effect on jaw bones. Osteoporotic women, who used bisphosphonates for 6 months minimum, will be invited to participate in this investigation. In addition, women with osteoporosis who are not under one of the bisphosphonates will be invited too, as a control. Control group will also include a number of osteopenic and normal women for comparison purposes, as these medications are not indicated for them. Women should be free of bone diseases other than osteoporosis or osteopenia.

On panoramic radiographs, radiographic bone density and mandibular cortical index will be assessed. Aluminum step-wedge will be used with panoramic radiography as it offers more accurate density measurements. In Cone-beam CT, radiographic density, apparent bone histomorphometric analysis and radiographic parameters of the periodontal disease will be assessed. Clinical measurements of periodontal disease will be recorded for two purposes. First, to adjust for the confounding factor (periodontal disease) when evaluating the trabecular bone between groups. Second, to test if using these drugs improve the periodontal status as their benefits are still controversial.
Pleuroperitoneal communication occurs when ascites moves from the abdominal cavity to the pleural cavity via a diaphragmatic fistula. Managing large pleural fluid volumes is challenging, often requiring an operation. Identifying small diaphragmatic fistulas during the operation can be problematic, but ensuring their detection improves outcomes. This video tutorial presents a recent empirical case in which we successfully identified and closed a pleuroperitoneal contact using a thoracoscopic surgical procedure aided by indocyanine green fluorescence imaging. The patient, a 66-year-old woman, was hospitalized due to acute dyspnoea from a right thoracic pleural effusion during hepatic ascites treatment for cirrhosis. Because ascites decreased with pleural fluid drainage, surgical intervention was considered due to suspicion of a pleuroperitoneal connection. During the operation, indocyanine green was injected intraperitoneally, and near-infrared fluorescence-guided thoracoscopy pinpointed the location of the diaphragmatic fistula. The fistula was sutured and reinforced with a polyglycolic acid sheet and fibrin glue. Detecting the fistula intraoperatively is crucial to prevent recurrence, and the indocyanine green fluorescence method is a safe and effective technique for detecting small fistulas.
PURPOSE: An antibacterial composition containing novel hispidin-based compounds is provided to suppress Fab I and Fab k enzyme activities and to ensure strong antibacterial function. CONSTITUTION: An antibacterial composition contains a compound of chemical formula 1 or 2, isomer thereof, derivative, or pharmaceutically acceptable salt thereof. The compound is prepared from Phellinus linteus 08090-29 strain. The composition has an antibacterial function from Staphylococus aureus, Bacillus subtili, Staphylococcus epidermis, methicillin-resistant Staphylococcus aureus(MRSA), quinolone-resistant Staphylococcus aureus(QRSA), or Streptococcus pneumonia. A composition for suppressing enoyl reductase contains the compound of chemical formula 1 or 2. An antibacterial quasi-drug composition contains the composition as an active ingredient.
The risk of cutaneous malignancies (including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma) is increased in patients treated with S1P receptor modulators. Use of MAYZENT has been associated with an increased risk of BCC and SCC. In Study 1, the incidence of BCC and SCC was 1.1% and 0.2%, respectively, in MAYZENT-treated patients [see Adverse Reactions (6.1)]. Cases of other cutaneous malignancies, including melanoma, have also been reported in patients treated with MAYZENT and in patients treated with other S1P receptor modulators. Kaposi’s sarcoma and Merkel cell carcinoma have also been reported in patients treated with S1P receptor modulators in the postmarketing setting.

Skin examinations are recommended prior to or shortly after the start of treatment and periodically thereafter for all patients, particularly those with risk factors for skin cancer. Providers and patients are advised to monitor for suspicious skin lesions. If a suspicious skin lesion is observed, it should be promptly evaluated. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. Concomitant phototherapy with UV-B radiation or PUVA photochemotherapy is not recommended in patients taking MAYZENT.
Trans-dl-1-n-propyl-6-oxodecahydro quinolines are separated into their optical isomers, [Ia! and [Ib!. The racemic mixt. soln. of trans-dl-1-n-propyl-6-oxodecahydroquinoline is reacted with dip- stolulyltartaric acid soln., and then separated into optical isomer of trans-1-n-propyl-6-oxodecahydroquinoline and di-ptoluoyl tartaric acid salt. The produced salts are treated with base, and then optically active isomers of trans-1-n-propyl-6oxodecahydroquinolines are separated.
When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
CNVs, which are a type of structural variation, make a substantial impact on diverse characteristics in multiple species. Q-PCR and data association analysis were used for STAT5A gene copy in this study. This study aimed to investigate the copy number variation (CNV) of the STAT5A gene in seven Chinese cattle breeds, namely Qinchuan cattle, Xianan cattle, Yunling cattle, Ji'an cattle, Jiaxian Red cattle, Qaidam cattle, and Guyuan yellow cattle. Blood samples were collected for CNV typing, and the correlation between CNV type and growth traits was analyzed using SPSS 23.0 software and ANOVA. The findings revealed variations in the distribution of different copy number types among the different cattle breeds. Furthermore, association analysis demonstrated a positive impact of CNV in the STAT5A gene on cattle growth: in the JX, individuals with duplication types exhibited superior performance in terms of rump length (P < 0.05). Conversely, normal GY cattle demonstrated better body height and abdomen circumference (P < 0.05), while QD cattle exhibited a significant correlation between weight and body length with normal individuals (P < 0.05). Moreover, QC bovine duplication individuals outperformed other types, with copy number variation significantly associated with chest depth, chest width, and body length (P < 0.05). The results validate the correlation between copy number variation (CNV) of the STAT5A gene and growth characteristics in five different cattle breeds, providing a reliable benchmark for the purpose of cattle breeding.
Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
PURPOSE:To obtain a composition for the oral cavity capable of promoting proliferation of gingival tissues, preventing swelling, edema, hemorrhage, etc., in inflammation and exhibiting excellent effects on prevention and treatment of periodontal diseases such as gingivitis and periodontitis. CONSTITUTION:A composition for the oral cavity is obtained by blending saikogenin A (R is beta-OH) and/or saikogenin D (R is alpha-OH) expressed by the formula as an essential ingredient with other ingredients. The amount of the aforementioned ingredient is preferably 0.0001-1.0wt.%, especially 0.001-0.1wt.% based on the total amount of the composition for the oral cavity. Furthermore, one or more compounds selected from a cell growth factor, tranexamic acid or derivative thereof are preferably used in combination to synergistically enhance effects of the compound expressed by the formula on periodontal diseases. Thereby, the objective composition for the oral cavity having the aforementioned effects is obtained. The amounts of the above-mentioned ingredients based on the total amount of the composition for the oral cavity are preferably 0.00001-0.1wt.% especially 0.0001-0.01wt.% cell growth factor and preferably 0.001-10wt.%, especially 0.01-5wt.% tranexamic acid or derivative thereof.
A nanoparticle formulated glycolipid antigen contains 2 components: 1). Nanoparticles at size of 10 to 2000 nm, composed by biodegradable polymers, such as poly(lactic acid), poly(glycolic acid), polycaprolactone, and other polyester species; polyothoesters species; polyanhydrides species and polyphosphazene species, as well as any copolymers composed by 2 or more than 2 polymers as mentioned. 2) 6-aminoethoxy-6-deoxy-alpha-galactosylceramide. The key technology applied to this invention is, component 2 is chemically conjugated to the surface of component 1, through amide linkage. The objection of this invention is to provide a novel surface conjugated formulation to a glycolipid antigen, which can stimulate immune system repeatedly in long term treatment of cancer and chronic viral infection status. The glycolipid conjugated to surface of nanoparticles can repeatedly stimulate NKT cells to produce IFN-g, a cytokine with potent anticancer and antiviral activities. This novel drug has been found to have anticancer effect in a mouse model of tumor metastasis.
Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
The 5:2 intermittent fasting (FAST) intervention consisted of two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule. The minimum amount of time to count as a fasting day was 24 hours, but patients were advised to aim for a complete fasting day including the nights before and after that day. On a fasting day, only water and unsweetened tea or coffee was allowed. However, given that fat is the macronutrient interfering the least with the metabolic adaptions to fasting, while carbohydrates disturb the most \[26\], patients were allowed to consume small amounts of bone broth/meat broth, coconut oil, butter/ghee or heavy cream as an "emergency plan", i.e., in case that they felt they needed some energy-containing foods to complete an initiated fasting day.

The primary study outcome was the feasibility of the FAST intervention and its effects on longitudinal body composition changes from baseline until the final week of radiotherapy (body mass, fat mass, fat-free mass, muscle mass, extracellular and total body water). Secondary endpoints were absolute changes in metabolic parameters, hormones, and overall quality of life scores in the FAST group. As a surrogate marker for insulin resistance, the triglyceride-glucose index (TyG) was calculated according to TyG=ln⁡(fasting triglycerides \[mg/dl\]×fasting glucose \[mg/dl\]/ 2).
PURPOSE: A film coating composition is provided to improve exterior quality and reduce production cost. CONSTITUTION: A film coating composition contains a hydroxypropylmethylcellulose, polyethyleneglycol and talc. The mass ratio of the hydroxypropylmethylcellulose and polyethyleneglycol is 1:0.22~1.25. The mass ratio of hydroxypropylmethylcellulose and talc is 1:0.8~3.8. The content of hydroxypropylmethylcellulose is 5-80 mass% based on total solid powder. The average molecular weight of polyethyleneglycol is 190-42,000. The composition further contains a coloring agent.
PURPOSE: Posterior fossa surgeries for pediatric tumors pose challenges in achieving optimal dural repair and duraplasty is usually required. Autografts, allografts, xenografts, and synthetic substitutes can be used for duraplasty. Autologous cervical fascia can be a safe and reliable graft option for duraplasty after posterior fossa surgeries. This study aims to investigate the outcomes of duraplasty with autologous cervical fascial graft in children after posterior fossa surgery for pediatric brain tumors.
METHODS: Pediatric patients with posterior fossa tumor who underwent surgery between March 2001 and August 2022 were retrospectively reviewed. Data on demographics, preoperative symptoms, diagnosis, tumor characteristics, hydrocephalus history, and postoperative complications, including cerebrospinal fluid (CSF) leakage, pseudomeningocele, and meningitis were collected. Logistic regression analysis was performed to explore risk factors for postoperative complications.
RESULTS: Patient cohort included 214 patients. Autologous cervical fascia was used in all patients for duraplasty. Mean age was 7.9 ± 5.3 years. Fifty-seven patients (26.6%) had preoperative hydrocephalus and 14 patients (6.5%) received VPS or EVD perioperatively. Postoperative hydrocephalus was present in 31 patients (14.5%). Rates of CSF leak, pseudomeningocele, and meningitis were 4.2%, 2.8%, and 4.2% respectively. Logistic regression analysis revealed that postoperative EVD and VPS placement were the factors associated with postoperative complications.
CONCLUSION: Autologous cervical fascia is a safe and reliable option for duraplasty with minimal risk of postoperative complications. The straightforward surgical technique and with no additional cost for harvesting the graft renders autologous cervical fascia a favorable alternative for resource-limited countries or surgical settings.
PURPOSE: To describe urologic complications associated with the surgical management of placenta accreta spectrum and determine their risk factors.
METHODS: A retrospective study was conducted on all patients diagnosed with abnormal invasive placentation who underwent surgery and delivered between 2002 and 2023 at a single expert maternity centre. Intra-operative and post-operative complications were described, with a special focus on urologic intra-operative injuries, including vesical or ureteral injuries. Univariate and multivariate analyses were performed to determine risk factors of intra-operative urologic injuries associated with placenta accreta spectrum surgical management. Additionally, using the Clavien-Dindo classification, the effects of intra-operative urologic injury and ureteral stent placement on post-operative outcome were evaluated.
RESULTS: A total of 216 patients were included, of which 47 (21.48%) had an intra-operative bladder and/or ureteral injury. Placenta percreta was associated with a higher rate of intra-operative urologic injury than placenta accreta (72.34% vs. 6.38%, p < 0.001). Multivariate analyses showed that patients who had placenta percreta and bladder invasion or emergency hysterectomy were associated with more intra-operative urologic injuries (OR = 8.07, 95% CI [2.44-26.75] and OR = 3.87, 95% CI [1.09-13.72], respectively). Patients with intra-operative urologic injuries had significantly more severe post-operative complications, which corresponds to a Clavien-Dindo score of 3 or more, at 90 days (21.28% vs. 5.92%, p = 0.004).
CONCLUSION: Surgical management of placenta accreta spectrum is associated with significant urologic morbidity, with a major impact on post-operative outcomes. Urologic complications seem to be correlated with the depth of invasion and the emergency of the hysterectomy.
A method for manufacturing the delayed release solid dosage form of Carbamazepine comprises the loading, mixing the ingredients, wetting the mixture, drying the mixture followed by the calibration, the powdering and the compression. Polyacrylate 30D aqueous dispersion is prepared. The mixture of microcrystalline cellulose, Carbamazepine, 1/3 of the required amount of colloid anhydrous silicone dioxide is dried to the residual humidity of 0.5-1.0%. To the granulate obtained, the rest of the required amount of colloid anhydrous silicone dioxide and crospovidon are added. The mixture obtained is mixed and calibrated through the sieve. The calibrated mass is powdered with magnesium stearate and compressed. The tablets 350 mg and 700 mg are produced.